<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01375166</url>
  </required_header>
  <id_info>
    <org_study_id>OPHT-070111</org_study_id>
    <nct_id>NCT01375166</nct_id>
  </id_info>
  <brief_title>Coupling of Neural Activity and Retinal Blood Flow in Diabetes</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of diabetes is increasing and the management of the disease is nowadays&#xD;
      considered a major challenge. Affected patients have increased mortality and morbidity as&#xD;
      well as a significant drop in the quality of life. The complications of diabetes can be&#xD;
      classified as microvascular (e.g. nephropathy, neuropathy or retinopathy) or macrovascular&#xD;
      (e.g. cardiovascular or cerebrovascular).&#xD;
&#xD;
      Several large-scale epidemiologic studies indicating that wider retinal venous caliber is&#xD;
      strongly associated with the fasting glucose level as well as with diabetes. Another retinal&#xD;
      vascular abnormality that is associated with diabetes is an abnormal retinal vascular&#xD;
      response to flicker stimulation. Retinal vessel dilatation in response to stimulation with&#xD;
      diffuse flicker light occurs due to a phenomenon called neurovascular coupling. This means&#xD;
      that increased activity of neurons is associated with an increased retinal metabolism. This&#xD;
      leads to a release of endogenous vasodilator substances and increased blood flow. However,&#xD;
      previous studies were limited by the fact that retinal vessel diameters and blood flow were&#xD;
      not measured simultaneously.&#xD;
&#xD;
      The present study aims to investigate whether the response of retinal vessel diameters and&#xD;
      blood flow velocities to flicker stimulation is altered in patients with diabetes. Both&#xD;
      parameters will be measured in real time using Fourier Domain Doppler OCT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    not enough subjects recruited&#xD;
  </why_stopped>
  <start_date type="Actual">March 6, 2013</start_date>
  <completion_date type="Actual">March 6, 2013</completion_date>
  <primary_completion_date type="Actual">March 6, 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retinal vessel diameters</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal blood flow velocities</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Diabetic retinopathy</arm_group_label>
    <description>Patients with early insulin dependent diabetes and no or mild non-proliferative retinopathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy</arm_group_label>
    <description>healthy control subjects</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        24 patients with early insulin dependent diabetes and no or mild non-proliferative&#xD;
        retinopathy, non-smokers 24 age and sex matched healthy controls, non-smokers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged over 18 years, nonsmokers&#xD;
&#xD;
          -  Normal findings in the medical history (except diabetes) and physical examination&#xD;
             unless the investigator considers an abnormality to be clinically irrelevant&#xD;
&#xD;
          -  normal laboratory findings (except diabetes associated parameters) unless the&#xD;
             investigator considers the abnormality to be clinically irrelevant&#xD;
&#xD;
          -  normal ophthalmic findings (except mild diabetic retinopathy), Ametropia less than 6&#xD;
             diopters&#xD;
&#xD;
          -  inclusion criterion of patients is type I diabetes with non or mild non-proliferative&#xD;
             retinopathy&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        Any of the following will exclude a healthy subject from the study:&#xD;
&#xD;
          -  Regular use of vasoactive drugs&#xD;
&#xD;
          -  Abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks&#xD;
             preceding the study&#xD;
&#xD;
          -  Symptoms of a clinically relevant illness in the 3 weeks before the first study day&#xD;
&#xD;
          -  Blood donation during the previous 3 weeks&#xD;
&#xD;
          -  History or presence of any ocular pathology&#xD;
&#xD;
          -  History or family history of epilepsy&#xD;
&#xD;
          -  Systemic hypertension defined as systolic blood pressure &gt;150mmHg, diastolic blood&#xD;
             pressure &gt;90mmHg&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
        Any of the following will exclude a subject with diabetes from the study:&#xD;
&#xD;
          -  Presence of non-insulin dependent diabetes, maturity onset diabetes of the young (MODY&#xD;
             diabetes)&#xD;
&#xD;
          -  History or presence of any other diabetes induced vascular pathologies or any other&#xD;
             ocular condition other then diabetic retinopathy&#xD;
&#xD;
          -  Best corrected visual acuity &lt;0.8&#xD;
&#xD;
          -  Previous laser photocoagulation treatment&#xD;
&#xD;
          -  Systemic hypertension defined as systolic blood pressure &gt;150mmHg, diastolic blood&#xD;
             pressure &gt;90mmHg&#xD;
&#xD;
          -  History or family history of epilepsy&#xD;
&#xD;
          -  Abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks&#xD;
             preceding the study&#xD;
&#xD;
          -  Symptoms of a clinically relevant illness in the 3 weeks before the first study day&#xD;
&#xD;
          -  Blood donation during the previous 3 weeks&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerhard Garh√∂fer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology, Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 11, 2011</study_first_submitted>
  <study_first_submitted_qc>June 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2011</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Gerhard Garhofer</investigator_full_name>
    <investigator_title>Assoc. Prof. Priv. - Doz. Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

